Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Cracking the mysteries of Alzheimer’s disease

With Pfizer shutting down its neuroscience unit and a long list of failed late-stage trials, the sheer difficulty of improving the treatment of Alzheimer’s disease has become painfully clear. How can researchers crack the mystery of this much-feared neurodegenerative disease?

Go Top